Trials / Completed
CompletedNCT01192971
A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma
Randomized, Open-label, Multi-center, Phase II Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial will be studying how well Apatinib working in patients with Hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | apatinib p.o. once daily for 4 weeks |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2010-09-01
- Last updated
- 2023-03-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01192971. Inclusion in this directory is not an endorsement.